Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been downgraded to Strong Sell in a statement by ValuEngine earlier today.

ValuEngine has downgraded Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to Strong Sell in a statement released on 7/06/2017.

Having a price of $3.47, Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) traded -2.68% lower on the day. With the last close down -44.07% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same period. Aeglea Bio Therapeutics Inc has recorded a 50-day average of $3.51 and a two hundred day average of $5.20. Volume of trade was down over the average, with 53,611 shares of AGLE changing hands under the typical 64,442

Performance Chart

With a total market value of $0, Aeglea Bio Therapeutics Inc has with a one year low of $2.81 and a one year high of $10.34 .

A total of 3 analysts have released a report on Aeglea Bio Therapeutics Inc. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $16.33.

More About Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.